Fingolimod, dimethyl fumarate, and teriflunomide could benefit patients more than glatiramer acetate and interferon beta.
LYON, FRANCE—Emerging oral therapies for multiple sclerosis (MS) may be more effective than established drugs such as interferon beta and glatiramer acetate, according to research presented at the 28th Congress of the European Committee for Treatment and Research in MS (ECTRIMS).
More Headlines